Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Jeffrey Infante, M.D.

JEFFREY INFANTE, M.D.

VICE PRESIDENT
EARLY CLINICAL DEVELOPMENT
ONCOLOGY

Jeffrey Infante, M.D. is Vice President, Early Clinical Development, Oncology, at Janssen.

Jeff is a world-renowned clinical investigator who has been involved in the development of many successful cancer drugs. He joined Janssen after a highly productive and successful decade in drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. At Sarah Cannon, Jeff served in many roles, including Director of the Drug Development Program, where he provided physician leadership to the Drug Development Unit in Florida, Oklahoma, Denver, and Nashville, which is one of the largest early phase clinical trial units for patients with advanced cancer in the country.

Prior to his tenure at Sarah Cannon, Jeff completed his fellowship in medical oncology at Johns Hopkins University School of Medicine. Over the course of his career, he has helped design and conduct many clinical trials ranging from first-in-human dosing through phase three registration trials. He has expertise with multiple novel treatments including molecularly targeted therapies, antibody drug conjugates and immuno-oncology agents.